3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
65
Neoplasms
31
Small Cell Lung Carcinoma
26
Carcinoma, Hepatocellular
24
Melanoma
23
Colorectal Neoplasms
23
Triple Negative Breast Neoplasms
20
Carcinoma, Renal Cell
20
Carcinoma, Transitional Cell
19
Breast Neoplasms
18
Neoplasm Metastasis
14
Urinary Bladder Neoplasms
13
Stomach Neoplasms
12
Uterine Cervical Neoplasms
11
Solid Tumors
11
Squamous Cell Carcinoma of Head and Neck
10
Ovarian Neoplasms
8
Lymphoma
7
Lung Neoplasms
7
Lymphoma, Non-Hodgkin
6
Head and Neck Neoplasms
6
Esophageal Neoplasms
6
Pancreatic Neoplasms
5
Liver Neoplasms
5
Carcinoma, Merkel Cell
5
Advanced Solid Tumor
5
Solid Tumor
4
Prostatic Neoplasms
4
Leukemia, Myeloid, Acute
4
Kidney Neoplasms
4
Interventions
pemigatinib
6
infigratinib
2
erdafitinib
2
derazantinib
2
pembrolizumab
1
exemestane
1
atezolizumab
1
Rogaratinib
1
INCB 54828-101
1
Gemcitabine
1
Fulvestrant
1
Drug Combinations
1
Carboplatin
1
Alpelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Acrocephalosyndactylia
×
atezolizumab
×
Clear all
NCT04045613
2023-10-13
FIDES-02
Basilea Pharmaceutica
Phase 1/2
Completed
95 enrolled
25 charts